There is also ongoing research developing gastrin-releasing peptide receptor (GRPR) antagonists, given its expression in early-stage hormone-sensitive cancers, unlike PSMA, which is more present in late-stage cancer [39,40]. The gene discussed is FOLH1; the disease is cancer.